ALMS — ALUMIS INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1847367 ·
Last close
$22.33
Market Cap
$2.76B
52W High
$30.06
52W Low
$19.86
ADV30
1,025,250
Next earnings
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,741,000 -98,409,000 -93,053,000 671,588,000 63,885,000 104,567,000
Dec 2025 1,929,000 -96,445,000 -92,931,000 411,940,000 89,670,000 110,643,000
Sep 2025 2,066,000 -115,292,000 -110,752,000 488,014,000 65,257,000 103,241,000
Jun 2025 2,666,000 -140,539,000 59,321,000 610,925,000 151,753,000 125,598,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-341,346,000
Investing CF
$56,810,000
Financing CF
$236,474,000
CapEx
$-1,145,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-4.04
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-901,876,000
Inventory
Receivables
$2,083,000
ST Investments
$218,831,000
EBIT TTM
$-453,804,000
Pretax Income TTM
$-251,886,000
Interest Exp TTM
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$8,402,000
EBITDA
$-435,260,992
Free Cash Flow
$-206,754,624
Enterprise Value
$2,320,094,464
Total Cash
$522,943,008
Total Debt
$35,664,000
Shares Out
123,432,072
Trailing EPS
$-1.78
Book Value
$4.46
ROE
-64.6%
ROA
-58.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 24,050,000 -453,804,000 -243,325,000 411,940,000 110,643,000 -369,523,000
Dec 2024 0 -300,754,000 -294,233,000 340,992,000 80,888,000 -255,078,000
Dec 2023 0 -158,174,000 -154,993,000 89,612,000 428,872,000 -129,975,000
Dec 2022 0 -113,850,000 -111,930,000 108,168,000 303,410,000 -107,722,000

TTM Snapshot

Revenues TTM
$2,066,000
NetIncome TTM
$-136,494,000
OpCashFlow TTM
$0
Assets (Latest)
$340,992,000
Forward EPS
$-2.95

Peers — same industry

TickerNameMarket CapLastDaily %
SLNO SOLENO THERAPEUTICS INC $2.76B $53.01
SUPN SUPERNUS PHARMACEUTICALS, INC. $2.77B $47.77
KLRA Kailera Therapeutics, Inc. $2.79B $21.57
GPCR Structure Therapeutics Inc. $2.81B $39.58
ARQT Arcutis Biotherapeutics, Inc. $2.64B $21.11

News headlines (Yahoo Finance, 1h cache)

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 14:33 · Yahoo
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?
2026-05-20 04:34 · Yahoo
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
2026-05-19 17:37 · Yahoo
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
2026-05-19 17:26 · Yahoo
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
2026-05-18 17:33 · Yahoo
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 18:33 · Yahoo
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 22:56 · Yahoo
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Oil Surge, Higher Yields, Geopolitical Uncertainty
2026-05-15 13:14 · Yahoo
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
2026-05-15 11:36 · Yahoo
A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss
2026-05-15 03:17 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.